The latest and largest was the Rapid Evidence Appraisal for COVID-19 Therapies (REACT) meta-analysis that included 27 RCTs with a total of 10 930 COVID-19 patients and 6,449 patients treated with IL-6r antagonists (IL-6Ra), representing 90% of all COVID-19 patients registered in IL-6Ra research trials (Shankar-Hari et al., 2021). The gene discussed is IL6R; the disease is COVID-19.